Significant Leadership Transition at PCI Biotech
PCI Biotech has made an impactful decision by promoting Morten Luhr to the role of Chief Scientific Officer (CSO), effective from the beginning of this year. His dedication and expertise have earned him this prestigious position within the company, succeeding Anders Høgset, who will take on a new role as Scientific Advisor, contributing to the team in a part-time capacity.
Employee Share Option Scheme Details
As part of this transition, the Board of Directors has approved the issuance of share options as a strategic move to foster commitment and align interests among management. A total of 75,000 share options have been granted to Morten Luhr, each offering the chance to acquire one share per option at a predetermined strike price of NOK 1.35. This rate is based on the average market price from the preceding five days of trading.
Vesting Conditions for Share Options
The awarded options are designed to vest annually, with one-third becoming available over a three-year period. Specifically, the first portion of options is slated to vest in the third quarter of 2025, culminating with full vesting by the third quarter of 2027. Importantly, the options have a lifespan until the third quarter of 2029, after which they will lapse if not exercised.
Commitment to Long-term Ownership
To encourage lasting equity ownership among the executive team, the options come with a commitment to hold any shares acquired through exercising these options for a minimum period of one year, unless a cash-less exercise is employed to cover taxes and transaction fees. The Board has expressed its expectation that each executive will maintain a shareholding equivalent to at least one year of their gross base salary before selling any shares.
Current Equity Holdings of Morten Luhr
With this latest tranche of options, Morten Luhr now possesses a total of 560,000 unexercised options and 70 shares, positioning him significantly within the company's equity structure. His role as a primary insider emphasizes the importance of his stake in PCI Biotech's future success.
Understanding Share Option Cap and Regulations
The Board of Directors established guidelines for these share options, which include a value cap. If the value cap, pegged at 20 times the strike price, is reached, all options will vest immediately, allowing for swift exercise. Moreover, notifications regarding primary insider transactions will be made public as mandated by market regulations, ensuring transparency in corporate governance.
Current Regulatory Authorisation
As per the latest authorisation dated May 24, 2024, a total of 2,790,000 share options can be awarded, out of which 2,463,334 have already been assigned. This structured approach underscores PCI Biotech's commitment to responsible and strategic governance, fostering a culture of growth and development among its leaders.
Contact Information for Further Inquiries
For any further details or inquiries related to this announcement, you can reach out to Ronny Skuggedal, the CEO of PCI Biotech, via email or mobile. Contact details are provided to ensure open communication and transparency.
Frequently Asked Questions
What has PCI Biotech announced recently?
PCI Biotech has promoted Morten Luhr to Chief Scientific Officer and granted him share options as part of his new role.
How many share options were awarded to Morten Luhr?
A total of 75,000 share options have been granted to Morten Luhr.
What is the strike price for the share options?
The strike price for the share options is NOK 1.35, based on the average trading price over the five days prior to the grant date.
What are the vesting conditions for the share options?
The options will vest over a three-year term, with one-third becoming available each year.
Who can I contact for more information about PCI Biotech?
For inquiries, please contact Ronny Skuggedal, CEO, at rs(a)pcibiotech.no or via mobile at +47 9400 5757.
